Flash update Santhera Valuation Report "Against all odds"

Monday, June 26, 2023 @ 12:00 am

The Catalyst licensing deal for vamorolone rights in North America, valued at up to USD 231 mn plus royalties, significantly improves the risk/reward profile for Santhera avoiding substantial dilution to raise cash for a US sales force, extends the cash runway into Q1 2025 and an experienced partner for North America.

Key catalysts include:

Vamorolone US approval in DMD - PDUFA (26 October 2023)
Vamorolone EU approval in DMD (Q4 2023)
Vamorolone UK approval in DMD (Q4 2023)

Read the full Santhera Valuation Report

You may also be interested in

Swiss Biotech Report 2025 highlights sector’s continuing resilience through commitment to international alliances

Total revenues remain strong at CHF 7.2 billion (CHF 7.3 billion in 2023) Record CHF 833 million raised by privately funded companies drives 22% overall rise in capital investment to CHF 2.5 billion (CHF 2.0 billion in 2023) Alentis Therapeutics (CHF 163 million) and SixPeaks Bio (CHF 102 million) lead the way in the private financing rounds Despite market headwinds, some public companies report n
May 6, 2025

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

ORYL introduces laser-based platform for measuring solubility and molecule aggregation

ORYL Photonics introduces the ORYL F1, a novel automated laser-based platform for the measurement of solubility and aggregation of drug molecules in the Life Science industry. This is a significant achievement for the fast-growing Swiss company and for the solubility and aggregation community. The laboratory instrument enables researchers to make faster decisions and gain a deeper understanding of
May 22, 2025

Cosmo valuation report: GI Genius, Winlevi, and Breezula to drive future growth

May 13, 2025

Pharvaris: Q1 2025 financial results and business update

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026 Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines TQT study waivers received from FDA for both deucrictibant extended-release f
May 13, 2025

Umlaut.bio: First-in-biology approach for therapies targeting tRNA modifications

First characterization of tRNA modifications that dysregulate mRNA stability of signaling pathways in cancer Umlaut.bio is an EMBL spin-off creating cancer and autoimmune therapeutics through small molecule inhibition of tRNA modifications With its senior executive team and a world-class advisory board, Umlaut.bio has started operations funded by HTGF, LBBW Venture Capital and L-Bank through the I
May 13, 2025